2. Search Result
Search Result
Results for "

Chromatin remodeling

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N6588
    3,4,5-Tricaffeoylquinic acid

    3,4,5-triCQA

    		 Akt NF-κB Inflammation/Immunology Cancer
    3,4,5-Tricaffeoylquinic acid (3,4,5-triCQA) inhibits tumor necrosis factor-α-stimulated production of inflammatory mediators in keratinocytes via suppression of Akt- and NF-κB-pathways. 3,4,5-Tricaffeoylquinic acid induces cell cycle arrest at G0/G1, actin cytoskeleton organization, chromatin remodeling, neuronal differentiation, and bone morphogenetic protein signaling in human neural stem cells. 3,4,5-Tricaffeoylquinic acid has the potential for the research of aging-associated diseases .
    3,4,5-Tricaffeoylquinic acid
  • HY-144874
    AZ3391

    		PARP Neurological Disease Cancer
    AZ3391 is a potent inhibitor of PARP. AZ3391 is a quinoxaline derivative. PARP family of enzymes play an important role in a number of cellular processes, such as replication, recombination, chromatin remodeling, and DNA damage repair. AZ3391 has the potential for the research of diseases and conditions occurring in tissues in the central nervous system, such as the brain and spinal cord (extracted from patent WO2021260092A1, compound 23) .
    AZ3391
  • HY-78695
    JQ-1 (carboxylic acid)
    5+ Cited Publications

    		 Epigenetic Reader Domain PD-1/PD-L1 Cancer
    JQ-1 carboxylic acid, a (+)-JQ-1 (HY-13030) derivative, is a potent BET bromodomain inhibitor. JQ-1 carboxylic acid can be used to synthesize PROTAC, which can target the degradation of BRD4.
    JQ-1 (carboxylic acid)
  • HY-141591
    CYT296

    		Others Others
    CYT296 is a target chromatin de-condensation compound. CYT296 can improve the induction of induced pluripotent stem cell (iPSCs) mediated by defined factors (OSKM) and induce an open chromatin state in Mouse Embryonic Fibroblast (MEFs) to facilitate somatic cell reprogramming. CYT296 can be used for cell replacement therapies and drug screening research .
    CYT296
  • HY-125209
    TH5427

    		Others Cancer
    TH5427 is a promising, targeted inhibitor that can be used to further study NUDT5 activity and ADP-ribose metabolism. TH5427, blocks progestin-dependent, PAR-derived nuclear ATP synthesis and subsequent chromatin remodeling, gene regulation and proliferation in breast cancer cells. NUDT5 is recently identified as a rheostat of hormone-dependent gene regulation and proliferation in breast cancer cells .
    TH5427
  • HY-125209A
    TH5427 hydrochloride

    		DNA/RNA Synthesis Cancer
    TH5427 hydrochloride is a potent, selective NUDT5 inhibitor (IC50=29 nM). TH5427 hydrochloride shows an apparent 690-fold selectivity for NUDT5 over MTH1. TH5427 hydrochloride blocks progestin-dependent, PAR-derived nuclear ATP synthesis and subsequent chromatin remodeling, gene regulation and proliferation in breast cancer cells .
    TH5427 hydrochloride
  • HY-161888
    DCSM06

    		Epigenetic Reader Domain Cancer
    DCSM06 is an inhibitor for the bromodomain of SWI/SNF chromatin remodeling complexe SMARCA2 with an IC50 of 9.7 μM
    DCSM06
  • HY-162739
    SMARCA2-IN-1

    		Epigenetic Reader Domain Cancer
    SMARCA2-IN-1 (Compound I-19) is an inhibitor for SWI/SNF chromatin remodeling complexe SMARCA2 with IC50 >1000 nM in H1299 .
    SMARCA2-IN-1
  • HY-W250163
    NAD+ lithium

    β-DPN lithium; β-NAD lithium; β-Nicotinamide Adenine Dinucleotide lithium

    		 Biochemical Assay Reagents Metabolic Disease
    NAD+ lithium (β-DPN lithium) is a lithium salt of nicotinamide adenine dinucleotide. NAD+ is a coenzyme in the REDOX reaction. NAD+ can directly or indirectly affect several key cellular functions, including metabolic pathways, DNA repair, chromatin remodeling, cell aging, and immune cell function .
    NAD+ lithium
  • HY-122645
    SMARCA2-IN-4

    		Epigenetic Reader Domain Cancer
    SMARCA2-IN-4 (Compound 26) is an inhibitor for SWI/SNF chromatin remodeling complexe SMARCA by targeting the bromodomains. SMARCA2-IN-4 exhibits high affinity for PB1(5), SMARCA2B and SMARCA4 with Kd of 124, 262 and 417 nM .
    SMARCA2-IN-4
  • HY-161887
    SMARCA2-IN-8

    		Epigenetic Reader Domain Cancer
    SMARCA2-IN-8 (Compound 13) is an orally active inhibitor for SWI/SNF chromatin remodeling complexe SMARCA2 (also known as Brahma homologue, BRM) and SMARCA4 (also known as Brahma-related gene 1, BRG1) with IC50 of 5 and 6 nM. SMARCA2-IN-8 inhibits the proliferation of SMARCA2 mutated cancer cell SKMEL5 with AAC50 of 5 nM. SMARCA2-IN-8 downregulates the SMARCA2-dependent KRT80 gene expression with AAC50 of 10 nM. SMARCA2-IN-8 exhibits antitumor efficacy and good pharmacokinetic characteristics in mice .
    SMARCA2-IN-8
  • HY-132242
    DL-Sulforaphane N-acetyl-L-cysteine

    SFN-NAC

    		 HDAC Apoptosis Drug Metabolite Cancer
    DL-Sulforaphane N-acetyl-L-cysteine (SFN-NAC) is an orally active HDAC inhibitor and metabolite of sulforaphane (HY-13755) with longer half-life and better blood-brain barrier permeability. DL-Sulforaphane N-acetyl-L-cysteine activates autophagy-mediated downregulation of α-tubulin expression through the ERK pathway and can be used in cancer research .
    DL-Sulforaphane N-acetyl-L-cysteine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: